Tourmaline Corp (TRML) - שולי רווח גולמי

The final gross margin of Tourmaline Bio, Inc. (TRML) highlights the potential for rent-seeking income from immune pathology therapies with long-term patent protection. The current level of 0.00 reflects this parameter against the backdrop of planned cash burn to fund clinical trials. Meanwhile, management is accelerating the testing program, seeking to promptly validate the therapeutic efficacy of its innovative treatment methods.
פילוחים אנליטיים ודוחות נתונים של חברת Tourmaline Bio, Inc. (TRML)

Tourmaline Bio, Inc. (TRML) development of drugs for rare immune pathologies determines the production cost structure, which is reflected in the value of 0.00. This metric measures the share of profit after deducting direct costs from total sales, allowing investors to assess operational efficiency and production cyclicality through the quarterly gross margin.